{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:54:58Z","timestamp":1765486498555},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologe"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00292-020-00816-6","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T12:53:09Z","timestamp":1599742389000},"page":"574-581","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fluoreszenz-in-situ-Hybridisierungen in der Diagnostik aggressiver B-Zell-Lymphome"],"prefix":"10.1007","volume":"41","author":[{"given":"Elena","family":"Gerhard-Hartmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"816_CR1","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2018.195958","volume":"104","author":"MR Ambrosio","year":"2019","unstructured":"Ambrosio\u00a0MR, Lazzi\u00a0S, Bello\u00a0GL et al (2019) MYC protein expression scoring and its impact on the prognosis of aggressive B\u2011cell lymphoma patients. Haematologica 104:e25\u2013e28","journal-title":"Haematologica"},{"key":"816_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3324\/haematol.2013.091827","volume":"99","author":"SM Aukema","year":"2014","unstructured":"Aukema\u00a0SM, Kreuz\u00a0M, Kohler\u00a0CW et al (2014) Biological characterization of adult MYC-translocation-positive mature B\u2011cell lymphomas other than molecular Burkitt lymphoma. Haematologica 99:726\u2013735","journal-title":"Haematologica"},{"key":"816_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/leu.2008.281","volume":"23","author":"EG Boerma","year":"2009","unstructured":"Boerma\u00a0EG, Siebert\u00a0R, Kluin\u00a0PM et\u00a0al (2009) Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a\u00a0historical review of cytogenetics in the light of todays knowledge. Leukemia 23:225\u2013234","journal-title":"Leukemia"},{"key":"816_CR4","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.3324\/haematol.2015.124305","volume":"100","author":"JF Ferreiro","year":"2015","unstructured":"Ferreiro\u00a0JF, Morscio\u00a0J, Dierickx\u00a0D et al (2015) Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain\/loss pattern. Haematologica 100:e275\u2013e279","journal-title":"Haematologica"},{"key":"816_CR5","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3324\/haematol.2018.207928","volume":"104","author":"B Gonzalez-Farre","year":"2019","unstructured":"Gonzalez-Farre\u00a0B, Ramis-Zaldivar\u00a0JE, Salmeron-Villalobos\u00a0J et al (2019) Burkitt-like lymphoma with 11q aberration: a\u00a0germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 104:1822\u20131829","journal-title":"Haematologica"},{"key":"816_CR6","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","volume":"18","author":"JL Hecht","year":"2000","unstructured":"Hecht\u00a0JL, Aster\u00a0JC (2000) Molecular biology of Burkitt\u2019s lymphoma. J\u00a0Clin Oncol 18:3707\u20133721","journal-title":"J Clin Oncol"},{"key":"816_CR7","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","volume":"114","author":"NA Johnson","year":"2009","unstructured":"Johnson\u00a0NA, Savage\u00a0KJ, Ludkovski\u00a0O et\u00a0al (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114:2273\u20132279","journal-title":"Blood"},{"key":"816_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00292-018-0440-z","volume":"40","author":"W Klapper","year":"2019","unstructured":"Klapper\u00a0W, Fend\u00a0F, Feller\u00a0A et\u00a0al (2019) Aggressive Bcell lymphomas: recommendations from the German Panel of Reference Pathologists in the Competence Network on Malignant Lymphomas on diagnostic procedures according to the current WHO classification, update 2017. Pathologe 40:152\u2013156","journal-title":"Pathologe"},{"key":"816_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/his.13959","volume":"76","author":"L Miao","year":"2020","unstructured":"Miao\u00a0L, Guo\u00a0N, Feng\u00a0Y et al (2020) High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. Histopathology 76:201\u2013211","journal-title":"Histopathology"},{"key":"816_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/ejh.12212","volume":"92","author":"MO Pedersen","year":"2014","unstructured":"Pedersen\u00a0MO, Gang\u00a0AO, Poulsen\u00a0TS et al (2014) MYC translocation partner gene determines survival of patients with large B\u2011cell lymphoma with MYC- or double-hit MYC\/BCL2 translocations. Eur J Haematol 92:42\u201348","journal-title":"Eur J Haematol"},{"key":"816_CR11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/j.1365-2559.2008.03042.x","volume":"52","author":"M Rodriguez-Justo","year":"2008","unstructured":"Rodriguez-Justo\u00a0M, Huang\u00a0Y, Ye\u00a0H et al (2008) Cyclin D1-positive diffuse large B\u2011cell lymphoma. Histopathology 52:900\u2013903","journal-title":"Histopathology"},{"key":"816_CR12","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1200\/JCO.19.00743","volume":"37","author":"A Rosenwald","year":"2019","unstructured":"Rosenwald\u00a0A, Bens\u00a0S, Advani\u00a0R et al (2019) Prognostic significance of MYC rearrangement and translocation partner in diffuse large B\u2011cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J\u00a0Clin Oncol 37:3359\u20133368","journal-title":"J Clin Oncol"},{"key":"816_CR13","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1182\/blood-2013-06-507996","volume":"123","author":"I Salaverria","year":"2014","unstructured":"Salaverria\u00a0I, Martin-Guerrero\u00a0I, Wagener\u00a0R et al (2014) A recurrent 11q aberration pattern characterizes a\u00a0subset of MYC-negative high-grade B\u2011cell lymphomas resembling Burkitt lymphoma. Blood 123:1187\u20131198","journal-title":"Blood"},{"key":"816_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","volume":"118","author":"I Salaverria","year":"2011","unstructured":"Salaverria\u00a0I, Philipp\u00a0C, Oschlies\u00a0I et al (2011) Translocations activating IRF4 identify a\u00a0subtype of germinal center-derived B\u2011cell lymphoma affecting predominantly children and young adults. Blood 118:139\u2013147","journal-title":"Blood"},{"key":"816_CR15","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1182\/blood-2017-12-820605","volume":"131","author":"DW Scott","year":"2018","unstructured":"Scott\u00a0DW, King\u00a0RL, Staiger\u00a0AM et al (2018) High-grade B\u2011cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B\u2011cell lymphoma morphology. Blood 131:2060\u20132064","journal-title":"Blood"},{"key":"816_CR16","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017","unstructured":"Swerdlow\u00a0SH, Campo\u00a0E, Harris\u00a0NL, Jaffe\u00a0ES et\u00a0al (Hrsg) (2017) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4.\u00a0Aufl. IARC Press, Lyon","edition":"4"},{"issue":"Suppl 5","key":"816_CR17","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly\u00a0H, Gomes Da Silva\u00a0M, Vitolo\u00a0U et al (2015) Diffuse large B\u2011cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v116\u2013v125","journal-title":"Ann Oncol"},{"key":"816_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3109\/10428194.2010.540361","volume":"52","author":"T Vela-Chavez","year":"2011","unstructured":"Vela-Chavez\u00a0T, Adam\u00a0P, Kremer\u00a0M et al (2011) Cyclin D1 positive diffuse large B\u2011cell lymphoma is a\u00a0post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leuk Lymphoma 52:458\u2013466","journal-title":"Leuk Lymphoma"},{"key":"816_CR19","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1182\/blood-2018-07-864025","volume":"133","author":"R Wagener","year":"2019","unstructured":"Wagener\u00a0R, Seufert\u00a0J, Raimondi\u00a0F et al (2019) The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 133:962\u2013966","journal-title":"Blood"},{"key":"816_CR20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243071","author":"L Wang","year":"2020","unstructured":"Wang\u00a0L, Tang\u00a0G, Medeiros\u00a0LJ et\u00a0al (2020) MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.243071","journal-title":"Haematologica"},{"key":"816_CR21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.235556","author":"M Ziepert","year":"2020","unstructured":"Ziepert\u00a0M, Lazzi\u00a0S, Santi\u00a0R et al (2020) A 70\u202f% cut-off for MYC protein expression in diffuse large B cell lymphoma identifies a\u00a0high-risk group of patients. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.235556","journal-title":"Haematologica"}],"container-title":["Der Pathologe"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-020-00816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-020-00816-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-020-00816-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T23:32:54Z","timestamp":1631143974000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-020-00816-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s00292-020-00816-6","relation":{},"ISSN":["0172-8113","1432-1963"],"issn-type":[{"value":"0172-8113","type":"print"},{"value":"1432-1963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"9 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Gerhard-Hartmann und A.\u00a0Rosenwald geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}